Pirisi M, Fabris C, Falleti E, Soardo G, Toniutto P, Gonano F, Bartoli E
Cattedra di Medicina Interna, Università degli Studi, Udine, Italy.
Clin Chim Acta. 1993 Oct 15;219(1-2):47-55. doi: 10.1016/0009-8981(93)90196-b.
We measured serum erythropoietin (EPO) immunoenzymatically in 245 subjects (151 male, 94 female) to investigate the pathophysiology of its liberation in patients with liver disease. Twelve patients had acute hepatitis, 60 mild chronic liver disease (CLD), 50 cirrhosis (CIR), 43 hepatocellular carcinoma (HCC), 16 malignant extrahepatic disease, 32 benign extrahepatic disease (BEN); 32 subjects served as healthy controls. Higher EPO levels were found in all groups of patients as compared with controls (Bonferroni's test, P < 0.01); CIR and HCC had higher values than CLD and BEN (P < 0.01). By multiple regression analysis, EPO correlated with haematocrit, cholinesterase and C-reactive protein (F = 18.63, P < 0.0001). Thus, circulating EPO increases in patients with liver disease, particularly in its more advanced forms. Besides anaemia, both impairment of liver function (possibly via decreased EPO metabolism) and inflammation seem to play contributory roles in elevating serum EPO.
我们采用免疫酶法对245名受试者（151名男性，94名女性）的血清促红细胞生成素（EPO）进行了检测，以研究肝病患者中EPO释放的病理生理学机制。其中12例为急性肝炎患者，60例为轻度慢性肝病（CLD）患者，50例为肝硬化（CIR）患者，43例为肝细胞癌（HCC）患者，16例为肝外恶性疾病患者，32例为肝外良性疾病（BEN）患者；32名受试者作为健康对照。与对照组相比，所有患者组的EPO水平均较高（Bonferroni检验，P < 0.01）；CIR组和HCC组的值高于CLD组和BEN组（P < 0.01）。通过多元回归分析，EPO与血细胞比容、胆碱酯酶和C反应蛋白相关（F = 18.63，P < 0.0001）。因此，肝病患者，尤其是病情更严重的患者，循环EPO水平会升高。除贫血外，肝功能损害（可能通过降低EPO代谢）和炎症似乎在血清EPO升高方面都起到了一定作用。
